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After years of nihilism towards the use of chemotherapy for non small cell lung cancer in the UK it would appear that we have
now reached the point where the use of chemotherapy to relieve symptoms, maintain quality of life, and prolong life, are now
accepted for informed patients with good performance status willing to accept short-term toxicities. The use of the new
agents vinorelbine, gemcitabine and paclitaxel in combination with cisplatin or carboplatin are all active regimens which offer
small but real advantages over standard UK triple therapies (MVP, MIC) in terms of resource use, toxicity proﬁles and
response rates. Overall survival could be increased by as much as 10% at one year on indirect comparisons. The use of
docetaxel as second line therapy now offers lung cancer patients a second bite of the cherry, and should overall also prolong
survival. It is only in embracing these small gains that we can currently make progress in the treatment of NSCLC.
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The widespread nihilism in the UK towards palliative lung cancer
treatment has meant that patients with all stages of lung cancer
have been deprived of treatment that adds small survival gains
and improved symptom relief. This may contribute to the overall
dismal outcome survival ﬁgures for lung cancer in the UK (Jans-
sen-Heijnen et al, 1998). At this time chemotherapy is
sufﬁciently active to justify its use in patients of good performance
status who understand the true goals of chemotherapy and its
potential toxicities – but what should we use? The current ques-
tions regarding palliative chemotherapy in the UK remain – is
any doublet of the new or old generation better than UK triple
therapy for patients of performance status zero or one, and can
single agent chemotherapy replace UK triple therapy for patients
of performance status two? This review will examine the data in
support of the new agents that have been assessed by the National
Institute of Clinical Excellence in an attempt to answer these ques-
tions.
CURRENT STANDARDS
The commonest (standard) treatments for non-small cell lung
cancer (NSCLC) in this country are cisplatin based, usually MVP
(mitomycin C, vinblastine and cisplatin) or MIC (mitomycin C,
iphosphamide and cisplatin) with cisplatin used at a dose of
around 50–60 mg m
72. This differs to the United States where
the cisplatin dose is usually higher and the combinations most
frequently used until the late 1990s were etoposide plus cisplatin
and vinblastine or vindesine with cisplatin. These regimens have
been directly compared in several trials. One of these trials
compared MIC, MVP and etoposide/cisplatin and showed a signif-
icant survival advantage for both three drug regimens (median
survival 36 weeks, 42 weeks, and 27 weeks respectively; P50.04)
(Crino et al, 1995). Other randomised trials did not report any
advantages with the cisplatin triplets (Ruckdeschel et al, 1986;
Crino et al, 1990).
The use of higher cisplatin doses was based on one small rando-
mised trial involving 85 patients, that demonstrated a longer
duration of response and a survival advantage for responders in
the higher dose arm but overall survival was not reported (Gralla
et al, 1981). However, three subsequent larger randomised studies
have failed to show an advantage for the higher cisplatin doses
and toxicity was considerably worse (Table 1) (Gandara et al,
1993; Klastersky et al, 1986; Felip et al, 1997). Thus UK oncologists
tend to use cisplatin at a dose of 50 mg m
72 in triple therapy
given three-weekly, and this is also well tolerated by performance
status-two patients (Smith et al, 2001).
The standard duration of chemotherapy has also recently been
challenged. A trial of MVP chemotherapy showed that three
courses produced the same symptomatic beneﬁts and response
rates as six. Haematological toxicity increased during courses four
to six in patients randomised to receive six courses with grade 3–4
leucopenia in 22% and grade 3–4 thrombocytopenia in 7%
compared with 12% and 1% respectively in the patients rando-
mised to receive three courses (Smith et al, 2001). The median
survival was 6 vs 7 months in the two arms, and the 1-year survival
was 22% vs 25% (P=0.2). In the subgroup of patients of perfor-
mance status 0 and 1 the 1-year survival was no different at
25.6% (95% CI, 20.8–32.5%), and performance status did not
come out as an independent prognostic factor in this trial. Quality
of life deteriorated after the fourth course in the group having six
courses of chemotherapy. These results were corroborated by a
recently reported trial comparing treatment with a combination
of carboplatin and paclitaxel for four cycles or continued until
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www.bjcancer.comdisease progression. Survival and quality of life were the same in
the two treatment arms, as was the median number of chemother-
apy cycles delivered (Socinski et al, 2001). Most centres now treat
NSCLC with 3–4 courses of palliative chemotherapy. This of
course has major health economic implications.
In patients who are not suitable for cisplatin based treatment,
carboplatin can be used instead on the basis that for most solid
tumours carboplatin produces similar palliative beneﬁts to cispla-
tin. The three-drug combination mitomycin C, vinblastine and
carboplatin (MVCarbo) is given as a day case, and appears to be
as active as MVP but with more myelosuppression, with rates of
grade 3–4 leucopenia of 24% and grade 3–4 thrombocytopenia
of 22% (Gregory et al, 2001). The drug costs for MVCarbo are
about the same as for single agent vinorelbine or gemcitabine.
Two randomised trials have addressed whether carboplatin can
replace cisplatin in standard lung cancer chemotherapy regimens.
The ﬁrst trial, conducted by the EORTC, evaluated cisplatin or
carboplatin in combination with etoposide, using a cisplatin dose
of 120 mg m
72 and a carboplatin dose of 325 mg m
72 (Klastersky
et al, 1990). Two hundred and twenty-eight eligible patients were
randomised among whom response rates were 16% in the carbo-
platin arm and 27% in the patients treated with cisplatin
(P=0.07). No survival difference was demonstrated (median survi-
val 27 vs 30 weeks; P=0.35), and higher rates of toxicity were seen
with the cisplatin regimen. In the second trial involving 221
patients, the regimen investigated was mitomycin, vinblastine and
platinum, using either cisplatin 120 mg m
72 or carboplatin
500 mg m
72 (Jelic et al, 2001). Thus the carboplatin:cisplatin dose
ratio was greater in this study. Response rates were identical in the
two arms (37% vs 36%; P40.9), but both progression-free survival
(P=0.005) and overall survival (P=0.008) favoured the carboplatin
regimen. The authors do not report median survival times or the
proportion of patients surviving for 1 year and it is therefore difﬁ-
cult to ascertain the clinical relevance of this difference.
Furthermore, a signiﬁcant imbalance between the two arms was
found in relation to performance status, with a signiﬁcantly greater
proportion of performance status 0 and 1 patients in the carbopla-
tin arm. In this trial the carboplatin regimen produced signiﬁcantly
more haematological toxicity whereas the cisplatin regimen was
more emetogenic. On a cautionary note, a numerically inferior
survival was produced by a regimen of carboplatin and docetaxel
compared with a cisplatin/docetaxel combination (median survival
9.1 months vs 10.9 months). However, this randomised trial was
designed to compare each of these regimens with a control arm
of cisplatin plus vinorelbine and was not powered to examine
the difference between the two docetaxel-containing arms (Rodri-
guez et al, 2001). The carboplatin/cisplatin debate goes on and a
trial to deﬁnitively answer this question will need careful design
and large numbers of patients.
BACKGROUND TO THE NEW DRUGS
Gemcitabine, the taxanes (paclitaxel, docetaxel), and vinorelbine all
have signiﬁcant single agent activity with response rates of at least
20% and encouraging survival data with acceptable toxicities. It is
gratifying to see that they have all been tested against best suppor-
tive care in NSCLC (Table 2). Similarly all four drugs have been
combined with cisplatin with predictable toxicity and higher
response rates than are achieved with cisplatin alone – this data
will not be enlarged upon as single agent cisplatin is not a usual
therapy in the UK. On the other hand there is little data on the
use of a new agent with cisplatin versus a new agent alone, vinor-
elbine being the drug with the most data on this issue to date.
However a recently completed study in the US compared paclitaxel
plus cisplatin with single agent paclitaxel, and the results are
awaited with interest (Lilenbaum et al, 2001). More recently a
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Table 2 Chemotherapy vs Best Supportive Care (BSC) in untreated patients with non small cell lung cancer
Objective Median survival 1-year Quality
Number PS response rate (months) survival of life Symptoms Reference
Cisplatin 778 NR NR 1 15% NR NR Meta-analysis
BSC 2.5 5% 1995
MIC 351 0–2 32% 6.7 25% + + Cullen, 1999
BSC – 4.8 17% (P=0.03)
MVP/IEP 287 0–2 42%/40% 8.1/5.9 39%/30% + NR Thongprasert, 1999
BSC – 4.1 (P=0.0003) 13%
Vinorelbine 161 0–2 19.7% 6.75 32% + + Gridelli, 1999
BSC – 5.25 (P=0.03) 14% (P=0.04)
Gemcitabine 300 0–2 33%
a NS + + Anderson, 1999
BSC 12.7%
a
Paclitaxel 157 0–2 16% 6.8 32% + NR Ransom, 2000
BSC – 4.8 25%
Docetaxel 207 0–2 13.1% 6 25% + + Roszkowski et al, 2000
BSC – 5.7 16% (P=0.026)
aSymptom response; M=mitomycin C; I=iphosphamide; C=cisplatin; V=vinblastine; E=etoposide; NR=not reported; NS=not
signiﬁcant; +=improvement in parameter.
Table 1 Comparison of high and low-dose cisplatin in untreated patients
with non small cell lung cancer
Treatment Objective Mean survival
arms Number response rate (months) Reference
VdCis (60) 85 46% 10 (in responders) Gralla et al,
VdCis (120) 40% 22 (in responders) 1981
ECis (60) 241 25% NS Klastersky et al,
ECis (120) 29% 1986
Cis (50 d1+8) 356 12% 6.9 Gandara et al,
Cis (100 d1+8) 14% 5.3 1993
MCis (100 d1+8) 27% (P50.05) 7.2 (P=0.53)
MICis (50)
a 72 48% NS Felip et al,
MICis (100)
a NS 1997
aPreoperative chemotherapy for stage IIIA NSCLC; Vd=vindesine; Cis=cisplatin;
E=etoposide; M=mitomycin C; NS=no signiﬁcant difference between arms; Figures
in brackets refer to cisplatin dose in mg m
72 – all regimens are 3-weekly except
days 1+8 regimens which are 4-weekly.
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mised trials.
CLINICAL EFFECTIVENESS OF VINORELBINE
Vinorelbine vs best supportive care
A large randomised phase III trial, compared vinorelbine to best
supportive care alone in 191 elderly patients (over 70 years) with
NSCLC stages IIIb or IV, WHO performance status 0–2 (Elderly
Lung Cancer Vinorelbine Italian Study Group, 1999). The primary
end point was improvement in quality of life. Secondary endpoints
were toxicity and tumour response in the vinorelbine arm. Vinor-
elbine treated patients had an improved quality of life, measured as
improvement in physical, cognitive and social functioning
compared to patients treated with best supportive care only. Trea-
ted patients also recorded improvements in disease related
symptoms (cough, dyspnoea, pain, fatigue) but worse toxicity-
related symptoms (constipation, nausea and vomiting, peripheral
neuropathy and hair loss). Survival rates for the vinorelbine-treated
patients at 6 and 12 months were 55% and 32%, compared to 41%
and 14% in the control group. Median survival increased from 21
to 28 weeks (P=0.03). After adjustment for stage of disease and
performance status, the estimated relative hazard of death for the
vinorelbine-treated patients was 0.65 (95% conﬁdence interval
[CI], 0.45–0.93) compared to those in the control arm. The objec-
tive overall response rate (ORR) in the vinorelbine-treated patients
was 19.7% with a further 30.3% having stable disease, while 42.1%
had progressive disease. Vinorelbine treatment was generally well
tolerated by the majority of patients. Only ﬁve patients stopped
treatment due to toxicity (Elderly Lung Cancer Vinorelbine Italian
Study Group, 1999) (Table 2).
A similar study of 211 patients with stage IV NSCLC rando-
mised patients to either vinorelbine or a control arm of 5-
ﬂuorouracil (5-FU) on a 2:1 ratio. The FDA chose the control
arm of 5-FU, as it was not considered ethical to randomise against
no treatment. The primary endpoints were survival and quality of
life with response rates the secondary end point. The outcome
favoured vinorelbine in terms of both median survival (30 vs 22
weeks, P50.03) and the proportion of patients alive at 1 year
(25% vs 16%) (Crawford et al, 1996).
Vinorelbine in combination with cisplatin vs other
standards
Vinorelbine plus cisplatin has been compared with single agent
vinorelbine. In a three-arm study, 612 patients of performance
status 0, 1, and 2 were randomised between vinorelbine/cisplatin,
vindesine/cisplatin and vinorelbine alone. The vinorelbine/cisplatin
combination resulted in a signiﬁcantly superior response rate and
survival (Table 3) (Le Chevalier et al, 1994). More recent analysis
of this data has shown that the subgroup of patients with perfor-
mance status 2 had more toxicity and less beneﬁt from
vinorelbine and cisplatin when compared to vinorelbine alone
(Le Chevalier et al, 2001). Two smaller randomised studies
compared vinorelbine/cisplatin to vinorelbine alone and showed a
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Table 3 New agents alone or in combination with platinum compared with standard regimens in untreated patients with stage IIIB and IV non small cell
lung cancer
Objective Median 1-year
Treatment arms Number PS response rate survival (months) survival Reference
Vinorelbine
VdCis 602 79% 0–1 19% (P=0.02)
b 7.5 (P=0.04)
b 27% Le Chevallier et al, 1994
VrlCis 30% 9.3 35% Le Chevallier et al, 2001
Vrl 14% (P50.001)
b 7.2 (P=0.01)
b 30%
MVdCis (100) 247 NR 41% No signiﬁcant NR Galetta et al, 2000
VrlCis 38% difference
MVCis 158
a NR 36.7% NR 17% Costa et al, 2000
VrlCis 50% 40% (P50.05)
Gemcitabine
CisEtop 147 0–2 15.3% 7.6 24% Ten Bokkel Huinink et al, 1999
Gem 17.9% 6.6 26%
CisEtop 53 79% 0–1 20.8% 11.2 NR Perng et al, 1997
Gem 19.2% 8.6
CisEtop 135 85% 0–1 21.9% 7.2 26% Cardenal et al, 1999
GemCis 40.6% (P=0.02) 8.7 32%
MVCis 158
a NR 36.7% NR 17% (P50.05) Costa et al, 2000
CisGem 54.8% 33%
GemCis 53.1% 39%
MICis (100) 307 94% 0–1 26% 9.6 33% Crino et al, 1999
GemCis 38% (P=0.029) 8.6 (P=0.877) 34%
MVCis/MICis 232 NR 33% NR NR Danson et al, 2001
GemCarbo 32%
Paclitaxel
CisEtop 574 0–1 12% 7.6 (P=0.048)
c 32% Bonomi et al, 2000
Pac(135)Cis 27% 9.5 37%
Pac(250)Cis 32% 10 40%
TenCis 302 89% 0–1 25% 9.3 39% Giaccone et al, 1998
PacCis 36% (P=0.03) 8.9 39%
UK Standards
MICis (50) 351 60% 0–1 32% 6.7 25% Cullen, 1999
MVCis (50) 308 74% 0–1 31% 5.6 25% Smith et al, 2001
Vd=vindesine; Cis=cisplatin; Vrl=vinorelbine; M=mitomycin C; V=vinblastine; Etop=etoposide; Gem=gemcitabine; I=iphosphasmide; Carbo=carboplatin; Pac=paclitaxel;
Ten=tenipsoide; NR=not reported;
aTotal number of patients in 4-arm trial (see text);
bCompared to VrlCis arm;
cCompared to combined paclitaxel arms.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(5), 481–490non signiﬁcant trend to improved survival: 41 vs 33 weeks (Gil
Deza et al, 1996), and 33 vs 32 weeks (Depierre et al, 1999).
Two randomised clinical trials have compared vinorelbine plus
cisplatin with standard cisplatin-based triplets. An Italian group
has recently updated their study and presented it at the World
Lung Cancer Meeting in Japan in September 2000. A total of
247 patients have been randomised to cisplatin and vinorelbine
(VrlCis) or MVdP (cisplatin 100 mg m
72, vindesine and mitomy-
cin C). There was no statistically signiﬁcant difference between
response rates (38% VrlCis and 41% MVdP), time to progression
or overall survival. The VrlCis arm had more phlebitis and the
MVdP arm had more myelosuppression and thrombocytopenia.
The authors concluded VrlCis was as active as MVdP but less toxic
(Table 3) (Galetta et al, 2000).
A Portuguese group have reported on the ﬁrst 158 patients of a
planned 240 entered in a randomised Phase III trial comparing
MVP (mitomycin, vinblastine, cisplatin) vs VrlCis (vinorelbine
and cisplatin) vs CisGem (cisplatin d1 and gemcitabine) vs GemCis
(gemcitabine and cisplatin d15 and q28). The results are detailed in
Table 3, demonstrating the superior activity of cisplatin combined
with vinorelbine or gemcitabine vs MVP. However, this study was
reported early and may well be underpowered to show a survival
beneﬁt. Further details of the patient population are also required
(Costa et al, 2000).
CLINICAL EFFECTIVENESS OF GEMCITABINE
Gemcitabine was launched in 1995 – the same year as the meta-
analysis (Non-small Cell Lung Cancer Collaborative Group,
1995). Phase II studies in NSCLC showed both activity and symp-
tom control. An overall response rate of 20% was observed in the
Manchester/Copenhagen study (and veriﬁed by an independent
oncology review board), and 51 out of 73 patients (70%) reported
an improvement in their tumour related symptoms (Anderson et
al, 1994). Single agent gemcitabine has been studied in the elderly
with advanced NSCLC (Pasquini et al, 1998; Ricci et al, 2000).
Response rates and toxicity proﬁles were no different from other
phase II studies of single agents in younger patients.
Gemcitabine vs best supportive care
There is only one phase III study looking at single agent gemcita-
bine and comparing it to best supportive care (Anderson et al,
2000). This study randomised 300 patients and had as endpoints
the degree and durability of symptom response. The response rate
to gemcitabine was 19% (95% CI, 13–27%). Symptom response in
the two arms was assessed at 2, 4, and 6 months and was signiﬁ-
cantly better in the gemcitabine treated patients at 2 and 4 months
(P=0.048 and P=0.034) but was no different at 6 months. There
was a trend to improved QoL in the gemcitabine arm with dete-
rioration in the control arm over the ﬁrst 2-month period, and a
signiﬁcant reduction in the need for radiotherapy – 49% for
gemcitabine-treated patients vs 79% for controls. The most
impressive result in this study was the difference in the number
of days in hospital between the two study arms. Patients receiving
best supportive care required on average 2012 days in hospital and
247 in hospice compared with 1746 days in hospital and 183 days
in hospice for gemcitabine treated patients. There was no difference
in survival between the treatment arms in this study but the study
was underpowered to show this (Table 2).
Gemcitabine vs other standards
A Taiwanese trial and a separate European study compared gemci-
tabine alone to etoposide/cisplatin. The response rates and survival
were similar in both arms of both trials but the toxicity proﬁle and
inpatient days were markedly better in the gemcitabine arm (Perng
et al, 1997; ten Bokkel Huinink et al, 1999). Similarily gemcitabine
has been compared to cisplain and vindesine and again the single
agent was less toxic and as effective (Vansteenkiste et al, 2000).
These studies suggest gemcitabine can replace the older cisplatin
doublets in the palliative treatment of NSCLC – we do not know
if it can replace triplets including cisplatin and mitomycin C.
Gemcitabine in combination with cisplatin vs other
standard regimens
Gemcitabine/cisplatin is more active than cisplatin alone with a
response rate of 30.4% vs 11.1% (P50.0001) and a median survi-
val of 9.1 months versus 7.6 months. However, the combination is
more toxic for all haematological parameters (Sandler et al, 2000).
A Spanish study has compared gemcitabine/cisplatin (GemCis) to
cisplatin/etoposide (Cis/Etop). This study had both quality of life
and pharmacoeconomic analyses but for a phase III study the
number of patients included was small at 135 in total. The
response rate was higher with the new combination (40.6% vs
21.9%, P=0.02), the median duration of response was prolonged
by 6 weeks but the overall survival was not different and the
authors concluded the trial was underpowered to show a survival
difference (Table 3). Neutropenia was more common with Cis/
Etop while thrombocytopenia was more common with GemCis.
The quality of life showed no difference between the two treat-
ments (Cardenal et al, 1999) and pharmacoeconomic data is also
available (see cost effectiveness section) (Sacristan et al, 2000).
The most relevant trials for the UK are the comparisons of
GemCis/GemCarbo to MIC/MVP. There are now three completed
studies and a fourth in which this comparison is part of the four
arm design. In the ﬁrst reported by an Italian group (Table 3)
(Crino et al, 1999), the MIC used differed from the UK MIC in
that the cisplatin dose was 100 mg m
72 every 4 weeks while in
the UK the dose is 50–60 mg m
72 every 3 weeks. There were
307 patients randomised in this study. The overall response rate
was 38% for GemCis vs 26% for MIC (P=0.029). The median
survival time was 8.6 months vs 9.6 months respectively
(P=0.877). The incidence of severe neutropenia and anaemia was
the same for both arms but there was more severe thrombocytope-
nia with the GemCis treatment, 64% vs 28% (P50.001) and more
alopecia with MIC, 12% vs 39% (P50.001). The quality of life
results were not different between the two treatment arms. Surpris-
ingly this has lead to a change in practice in a number of European
countries with widespread usage of gemcitabine and cisplatin.
A UK study reported in abstract form compared a carboplatin/
gemcitabine regimen with MIC or MVP (Table 3) (Danson et al,
2001). At the time of this report, the outcome of 232 patients
was analysed, although over 300 patients had been enrolled in
the trial. Response rates were equivalent in the two arms (32%
vs 33%) with rates of stable disease slightly higher in the triplet
arm (26% vs 39%). Toxicity was reported to be similar between
the two groups although the gemcitabine/carboplatin arm
produced higher rates of haematological toxicity (P=0.006). Survi-
val data are awaited. The third study addressing this question is
also from the UK and has just been completed by the London
Lung Group. Again data should be available this year. Finally, as
discussed in the section on vinorelbine above, two different sche-
dules of cisplatin and gemcitabine were demonstrated to produce
higher response rates than MVP in a small four arm Portuguese
trial (Table 3) (Costa et al, 2000).
CLINICAL EFFECTIVENESS OF PACLITAXEL
Paclitaxel vs best supportive care
In one UK based trial 157 patients with advanced NSCLC, newly
diagnosed, with performance status 0, 1 or 2 were randomised to
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endpoint was survival and this was statistically signiﬁcantly
improved in the patients receiving paclitaxel with a median survi-
val of 6.8 months in the paclitaxel arm and 4.8 months in the
best supportive care arm (P=0.037). Quality of life was similar
for both treatment arms apart from the functional activity score
of the Rotterdam Symptom Checklist which was statistically in
favour of the paclitaxel arm (P=0.043) (Table 2) (Ranson et al,
2000).
Paclitaxel in combination with cisplatin vs other standard
regimens
The ﬁrst of the studies using paclitaxel (Taxol) in combination
with cisplatin started to appear around 1996. The ECOG study
compared two doses of paclitaxel (250 and 135 mg m
72) with
cisplatin to etoposide/cisplatin (Bonomi et al, 2000). Both paclitax-
el/cisplatin doses resulted in similar response rates, which were
higher than the etoposide/cisplatin arm (32% vs 27% vs 12%).
The median survival was extended by about 2 months (10 vs 9.6
vs 7.7 months, P=0.048) in the paclitaxel/cisplatin arms with an
improvement in the 1-year survival (39% vs 37% vs 32%). The
EORTC conducted a two-arm study comparing cisplatin and pacli-
taxel to cisplatin and teniposide and although the overall response
rate was higher with the paclitaxel treatment (36% vs 25%,
P=0.03), there was no survival difference between the two arms.
The quality of life was superior in the paclitaxel arm at 6 weeks
but this was lost at 12 weeks (Giaccone et al, 1998).
CLINICAL EFFECTIVENESS OF DOCETAXEL
Although NICE did not evaluate docetaxel as a ﬁrst line treatment
option, some data exists regarding its use in this setting. For
completeness this is reviewed below.
Docetaxel vs best supportive care
There is only one phase III study looking at single agent docetaxel
and comparing it to best supportive care (Roszkowski et al, 2000).
This study randomised 207 patients to either docetaxel at a dose of
100 mg m
72 or best supportive care. Patients of performance
status 0, 1, and 2 were all included. The response rate to docetaxel
was 13.1% (95% CI, 7.5–18.8%) and 19.6% in the evaluable
patients. Symptom response (pain and dyspnoea) was signiﬁcantly
better in the docetaxel treated patients with less use of opiate
analgesics (P50.001) and less need for palliative radiotherapy
(P50.01). There was a trend to improved quality of life in the
docetaxel arm for global health and physical functioning scores.
The emotional functioning was signiﬁcantly in favour of docetaxel
(P=0.01). There was a statistically signiﬁcant improvement in
median survival in docetaxel-treated patients, with a median survi-
val of 6 months compared to 5.7 months (P=0.026). This
translated to an improved 1-year survival rate of 25% compared
to 16% with best supportive care. At 2 years, 12% of the docetaxel
patients were alive whereas none remained alive after 20 months in
the best supportive care arm (Table 2).
Docetaxel in combination with cisplatin vs other standard
regimens
There is an ongoing trial comparing docetaxel plus cisplatin with
the standard regimens MVP or MIC in the UK. This combination
has been more extensively investigated in trials comparing the
different new doublet regimens, and will be discussed below.
TRIALS COMPARING THE NEW DRUG
COMBINATIONS
The favourable results with the newer agents discussed above has
led to these ‘platinum/new agent doublets’ being adopted as
standard chemotherapy regimens for advanced NSCLC in the
United States and in parts of Europe. Several trials have now
been conducted to examine whether any of these regimens stands
out as being superior to the rest. The majority of these trials
have only been the subject of reports in abstract form, and
the mature results are awaited. However, in general, little differ-
ence in efﬁcacy has been observed between the regimens studied,
while differences in toxicity have largely been qualitative rather
than quantitative.
Comparisons of platinum-containing doublets
At ASCO 2000 the ﬁrst results of the long awaited ECOG 1594 trial
were reported. This is one of the biggest trials in the palliative
treatment of lung cancer and has recruited over 1000 patients
(Schiller et al, 2000, 2002). The primary endpoint was survival.
There were no formal quality of life assessments or cost compari-
sons. Initially patients with performance status 0, 1, and 2 were
included. However, the poor outcome and toxicity in the perfor-
mance status 2 group resulted in this group being excluded from
the trial (Johnson et al, 1999; Schiller et al, 2002). The four treat-
ments compared were cisplatin/paclitaxel, cisplatin/gemcitabine,
carboplatin/paclitaxel and cisplatin/docetaxel. Table 4 shows the
results. The response rates were of the order of 20%, the median
survivals were all the same, and the percentage alive at 1 year
was 31–36%. The time to progression was 1 month better for
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Table 4 Comparisons of platinum-containing doublets in untreated patients with stage IIIB and IV non small cell lung cancer
Treatment arms Number PS Objective response rate Median survival (months) 1-year survival Reference
GemCis 1207 0–1
a 22% 8.1 36% ECOG, 1594
DocCis 17% 7.4 31% Schiller et al, 2002
Pac(24)Cis 21% 7.8 31%
Pac(3)Carbo 17% 8.1 34%
VrlCis 408 0–1 27% 8 36% SWOG, 9509
Pac(3)Carbo 27% 8 38% Kelly et al, 2001
VrlCis 1218 KPS NR 10.0 42% TAX 326 study
DocCis 80–100 10.9 (P=0.05)
b 47% Rodriguez et al, 2001
DocCarbo 9.1 (P40.05)
b 38%
VrlCis 612 0–1 31% 9.5 37% Scagliotti et al, 2001
GemCis 30% 9.8 37%
Pac(3)Carbo 32% 9.9 43%
Gem=gemcitabine; Cis=cisplatin; Pac=paclitaxel; Carbo=carboplatin; Vrl=vinorelbine; Doc=docetaxel; KPS=Karnofski performance status;
aInitially included PS 2 patients;
bCompared to VrlCis arm.
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(P=0.001).
In the South West Oncology Group (SWOG), vinorelbine
(25 mg m
72 week
71) and cisplatin (100 mg m
72 every 4 weeks)
was considered the standard chemotherapy. Their 9509 study
compared this arm with three-weekly paclitaxel (225 mg m
72) plus
carboplatin (AUC 6), as used in the ECOG study. The objective
response rate and median survival time were equivalent (27%
and 8 months) and the 1-year survival similar (36% compared
to 38%; P value, not signiﬁcant) (Table 4). Quality of life was simi-
lar with approximately 60% of patients having improved or stable
quality of life scores on both arms of the study. Toxicity appeared
to be greater among patients receiving cisplatin/vinorelbine, with
signiﬁcantly higher rates of severe neutropenia, leucopenia, nausea
and vomiting, whereas sensory neuropathy occurred signiﬁcantly
more frequently in the paclitaxel/carboplatin arm. This led to
discontinuation of therapy due to toxicity in 28% of patients trea-
ted with cisplatin/vinorelbine compared with 15% of those
receiving paclitaxel/carboplatin. However, the cost of treatment
with paclitaxel/carboplatin is several fold higher (Kelly et al, 2001).
The cisplatin/vinorelbine regimen has also acted as the standard
arm in two European studies, both enrolling patients of perfor-
mance status 0 and 1, and both reported at ASCO 2001. The
TAX 326 study was a large three arm trial in which the two other
regimens examined were docetaxel (75 mg m
72) plus cisplatin
(75 mg m
72) every 3 weeks and docetaxel (75 mg m
72) plus
carboplatin (AUC 6) every 3 weeks. This trial demonstrates an
improved quality of life with the lower dose of cisplatin but no
statistically signiﬁcant survival difference between arms after appli-
cation of the Bonferoni correction for multiple statistical tests. The
median survival was 10.9 months in the docetaxel/cisplatin arm
compared with 10 months in the cisplatin/vinorelbine arm
(P=0.05). The outcome in the docetaxel/carboplatin arm was not
statistically different from that in the cisplatin/vinorelbine arm with
a median survival of 9.1 months, and the rate of toxicity was lowest
in this arm (Fossella, 2001; Rodriguez et al, 2001). The second
study compared the same control arm of vinorelbine and cisplatin
with two other doublets, gemcitabine (1250 mg m
72 days 1 and 8)
plus cisplatin (75 mg m
72 day 2), and carboplatin (AUC 6, day 1)
plus paclitaxel (225 mg m
72 day 1), each on a three-weekly cycle.
The results are also shown in Table 4 and demonstrate no signiﬁ-
cant outcome differences between the three arms (Scagliotti et al,
2001).
Doublets without platinum
The perceived toxicity of platinum drugs has also led researchers to
investigate whether these can be omitted altogether. Two rando-
mised trials have investigated the combination of paclitaxel and
gemcitabine, and compared it with platinum-based doublets (Table
5). An EORTC three-arm trial compared three-weekly paclitaxel
(175 mg m
72 day 1) plus cisplatin (mg m
72 day 1) vs gemcitabine
(1250 mg m
72 days 1 and 8) plus cisplatin (80 mg m
72 day 1) vs
paclitaxel (175 mg m
72 day 1) plus gemcitabine (1250 mg m
72
days 1 and 8) (Van Meerbeeck et al, 2001). The differences between
these regimens did not reach statistical signiﬁcance, but there was a
trend towards a worse overall survival duration in the paclitaxel/
gemcitabine arm. As expected, the rates of severe nausea and
vomiting were lower in the paclitaxel/gemcitabine arm, but toxicity
was otherwise similar. It should be noted that this trial was
powered to detect a survival difference of 50% between regimens,
and therefore, like many of the trials discussed, was underpowered
to detect realistic small differences in efﬁcacy. The second trial
addressing this question was conducted in Greece, and compared
three-weekly paclitaxel (200 mg m
72 day 1) plus carboplatin
(AUC 6 day 1) with paclitaxel (200 mg m
72 day 1) plus gemcita-
bine (1000 mg m
72 days 1 and 8). This was also a relatively small
trial, enrolling 329 patients, and no statistically signiﬁcant outcome
differences were observed. However, low rates of severe toxicity
were seen in both arms of this study (Kosmidis et al, 2000). A third
trial also conducted in Greece has compared the combination of
docetaxel (100 mg m
72 day 8) plus gemcitabine (1100 mg m
72
days 1 and 8) with docetaxel (100 mg m
72 day 1) plus cisplatin
(80 mg m
72 day 2). Four hundred and forty-one patients were
randomised between the two arms, and all were supported with
granulocyte colony stimulating factor during chemotherapy.
Response rates were similar in the two groups (30.2% vs 32.4%)
and no differences were observed in time to tumour progression
or survival (Table 5). However, docetaxel plus gemcitabine had a
more favourable toxicity proﬁle with signiﬁcantly lower rates of
grade 3 or 4 neutropenia, nausea and vomiting and diarrhoea
(Georgoulias et al, 2001).
Two vs three drugs
A further question that has been addressed is whether adding a
third drug to existing doublets might enhance their activity. Thus,
triplets comprising cisplatin, gemcitabine and vinorelbine, and
cisplatin, gemcitabine and paclitaxel have been compared with a
cisplatin/gemcitabine doublet. Results are preliminary at present,
but no clear advantage of the three-drug regimens has emerged
to date, and toxicity is greater in comparison with this doublet
(Comella et al, 2000; Alberola et al, 2001). Similar results have been
produced in a comparison between the triplet vinorelbine, ipho-
sphamide, cisplatin and the doublet vinorelbine/cisplatin, with no
advantage for the triplet combination (Tan et al, 2001).
ELDERLY PATIENTS WITH NON-SMALL CELL LUNG
CANCER
Several trials have addressed the question of the optimal treat-
ment for patients aged over 70 years. As discussed above in
the section on vinorelbine, this drug was compared with best
supportive care in this patient group and demonstrated palliative
and survival beneﬁts. Subsequently, single agent vinorelbine
(30 mg m
72 days 1 and 8) was compared with a combination
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Table 5 Evaluation of non-platinum doublets in untreated patients with stage IIIB and IV non small cell lung cancer
Treatment arms Number PS Objective response rate Median survival (months) 1-year survival Reference
PacCis 480 0–2 31% 8.1 36% EORTC
GemCis 26% 8.8 33% Van Meerbeek et al, 2001
PacGem 27% 6.9 (P=0.09) 27%
PacCarbo 329 0–2 28.7% 10.7 41.3% Kosmidis et al, 2000
PacGem 36.5% 12.3 51.3%
DocCis 441 0–2 32.4% 10 42% Georgoulias et al, 2001
DocGem 30.2% 9.5 39%
Pac=paclitaxel; Cis=cisplatin; Gem=gemcitabine; Carbo=carboplatin; Doc=docetaxel.
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72 days 1 and 8) and gemcitabine
(1000 mg m
72 days 1 and 8), with both regimens given on a
three-weekly cycle. Planned enrolment was 240 patients, but
the trial was stopped early following a planned interim analysis
after the accrual of 152 patients, and analysis of response rates
and survival for the ﬁrst 120 patients entered in the trial. This
demonstrated the superiority of the combination treatment, with
a median overall survival of 29 weeks compared with 18 weeks
in the single agent vinorelbine arm, and a relative risk of death
after Cox multivariate analysis of 0.48 (95% CI 0.29–0.79;
P50.01). Toxicity was reported to show no signiﬁcant differ-
ences between the two arms (Frasci et al, 2000). However, a
second trial compared single agent vinorelbine with the combina-
tion of vinorelbine plus gemcitabine, and also incorporated a
third arm comprising single agent gemcitabine. This trial
included 698 patients and did not show any signiﬁcant differ-
ences between the combination and either single agent in
response rates, median overall survival or 1-year survival rates.
Furthermore, this trial demonstrated higher rates of myelosup-
pression with the combination treatment (Gridelli et al, 2001).
THE SECOND LINE TREATMENT OF NSCLC
Until recently, no agents have been available for use as a second
line chemotherapy for lung cancer. Docetaxel has now been
licensed for this purpose in Europe and in the USA. Two multicen-
tre randomised trials have examined docetaxel in the second line
treatment of lung cancer. The ﬁrst trial included 373 patients
and compared docetaxel to a control arm of vinorelbine or ipho-
sphamide. Neither of these drugs would be considered standard
second line treatment in this country. Docetaxel at a dose of
75 mg m
72 prolonged survival at 1 year (32% vs 19%, P=0.025),
prolonged time to progression (P=0.046) and prolonged the
progression free survival (P=0.005), but did not affect overall survi-
val. Quality of life data has not been reported yet (Fossella et al,
2000).
The second trial including 104 patients, comparing docetaxel to
supportive care alone, demonstrated a 2.4 month prolongation of
survival with docetaxel plus supportive care compared to supportive
care alone. Looking speciﬁcally at a docetaxel dose of 75 mg m
72
(which was better tolerated than 100 mg m
72) the median survival
prolongation was 2.9 months (7.5 months vs 4.6 months; P=0.01)
with an improved 1 year survival rate from 11% to 37% (P=0.003).
Global health status assessed by the EORTC QLQ-C30 quality of life
questionnaire favoured docetaxel. Outcomes were signiﬁcantly better
for pain and fatigue scales (P=0.006 and P=0.06 respectively), time to
deterioration in performance status, and there was a decreased need
for analgesia (P=0.01) and radiation therapy in the docetaxel arm.
Toxicity with docetaxel was manageable and surprisingly not signiﬁ-
cantly different from patients receiving best supportive care alone
(Shepherd et al, 2000). These improvements in outcome are compar-
able to those produced by irinotecan in the second line treatment of
colon cancer (Cunningham et al, 1998), data that has been used to
support the widespread adoption of this strategy in the UK (Table 6).
ECONOMIC ANALYSIS OF PALLIATIVE
CHEMOTHERAPY
The economic implications of palliative treatment for advanced
NSCLC may be substantial as this is the commonest solid tumour
in the UK and up to 40% of patients could become eligible for treat-
ment in the next 3–5 years compared to an average of 8% currently.
Most of the best health economic studies have been based in Canada.
The POpulation HEalth Model (POHEM) is a model developed by
the Health Analysis Modelling Group at Statistics Canada. This
model looks at direct cost until death. Comparing cisplatin, doxoru-
bicin and cyclophosphamide to best supportive care, the investigators
showed a prolongation of life of the order of 8 weeks but with this
there was a decrease in cost of the order of $949 (Canadian dollars)
per patient treated with chemotherapy due to the decreased need
for hospitalisation (Jaakkimainen et al, 1990). The cost of treating a
patient with best supportive care in Canadian dollars is $140895
and the cost with vinblastine and cisplatin, single agent vinorelbine,
outpatient vinorelbine and cisplatin, and outpatient etoposide and
cisplatin were all less than this. Thus these strategies are referred to
as ‘dominant’ in that they prolong survival and were less costly per
life year saved (LYS). Inpatient treatment was more costly than best
supportive care (Evans and Le Chevalier, 1996). A similar US based
study with a best supportive care arm showed again vinorelbine with
cisplatin was cost effective compared to vindesine and cisplatin
providing one LYS at a cost of $US15500 (Smith et al, 1995).
However, while this is valid for regimens that are low cost, or with
new single agents when compared to no chemotherapy, it may not
be the case when these new agents are combined with cisplatin as
patients may still need hospitalisation, and overall the treatments
may become very much more expensive. In the US-ECOG trial
(Bonomi et al, 2000), which showed some superiority of either pacli-
taxel/cisplatin regimen over cisplatin and etoposide, the cost per life
year saved (LYS) was an additional $30619 for the use of the paclitax-
el regimen (Earle and Evans, 1999). In the SWOG 9509 trial that
demonstrated equal efﬁcacy between the two treatment arms, an
economic analysis at 24 months demonstrated that the majority of
the cost difference was due to the additional cost of chemotherapy
between the two regimens tested. This was $11731 for paclitaxel
and cisplatin and $3498 for vinorelbine and cisplatin for drug costs
alone. All other supportive treatments e.g. blood products etc. were
equal with the two treatments (Ramsey et al, 2000).
In Spain a combination of gemcitabine and cisplatin was no
greater in total costs than MIC or cisplatin and etoposide (Carde-
nal et al, 1999; Sacristan et al, 2000). The cost of treating with
chemotherapy compared to best supportive care translated from
USA ﬁgures is about $15500 per LYS which compares favourably
with other health strategies e.g. dialysis for end stage renal failure
at $53000. It is also of the same order of magnitude as the use
of taxanes for breast cancer, which when evaluated and approved
by NICE was estimated to cost between £7000 and £24000 per
LYS. Health economic considerations change continually with
changing practice in giving chemotherapy over time. For instance
using rapid hydration to allow day case delivery of cisplatin reduces
bed occupancy, or conversely the use of growth factors leads to
higher costs.
There is only one UK study which details bed occupancy which
is the major non drug expense and this is the Manchester based
study comparing best supportive care to gemcitabine. Patients
receiving best supportive care required on average 2012 days in
hospital and 247 in hospice compared with 1746 days in hospital
and 183 days in hospice for gemcitabine treated patients. In addi-
tion the gemcitabine treated patients required less radiotherapy
(Anderson et al, 2000). This is of particular importance in the
UK where delays in radiotherapy delivery are commonplace due
to limited machine time. Second line treatment will be a new
added treatment cost with continuing drug development, particu-
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Table 6 Comparison of data in support of second line chemotherapy
treatment for patients with metastatic colorectal cancer with irinotecan
or stage IIIB/IV NSCLC with docetaxel
Irinotecan Docetaxel
No of patients in trials 635 477
Median survival gain (months) 3 2.9
1-year survival for treated patients 36.2% 37%
1-year survival for supportive care patients 13.8% 11%
Quality of life Beneﬁt Beneﬁt
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into clinical practice.
CONCLUSIONS
The National Institute for Clinical Excellence (NICE) has reviewed
the use of chemotherapy for the palliative treatment of non small
cell lung cancer in the year 2001. The volume of data on the use of
chemotherapy, both new and old, is impressive. Unlike the treating
doctors in the past, the committee felt that a prolongation of survi-
val by 6–8 weeks in a life that is predicted to be 6 months is
important. The beneﬁcial effects on quality of life and symptom
control further increase the value of this treatment. Their evalua-
tion of the new chemotherapy agents docetaxel, paclitaxel,
gemcitabine and vinorelbine for this disease was therefore in func-
tion of this and their recommendations were that these drugs
should be considered treatment options in accordance with their
licences. Thus paclitaxel, vinorelbine and gemcitabine are all
considered reasonable ﬁrst-line treatment options in combination
with cisplatin, and single-agent docetaxel is considered a suitable
second-line therapy. They concluded that the current evidence is
insufﬁcient to allow recommendation of a speciﬁc ﬁrst-line regi-
men as superior to the alternatives, but that patient and carer
preferences as well as economic considerations should play a part
in determining the appropriate treatment for an individual.
There remains considerable controversy as to whether the new
drug combinations provide a signiﬁcant advance over established
UK regimens such as MVP and MIC, largely due to the lack of
randomised clinical trials of sufﬁcient power comparing these
treatments. The results in terms of the percentage of patients
alive at 1 year using MVP and MIC in UK-based phase III
studies are included in Table 3. The disparity between these
ﬁgures and those produced in recent trials of the new generation
doublets could be due to differences in the patient populations
between the UK trials and those conducted in North America
and the rest of Europe. Alternatively, MIC and MVP may be
truly less active regimens. For a two-arm trial to show a 5–
8% difference in 1-year survival rate approximately 1000 patients
would be required, and such trials have not been performed to
date. Currently the market for these new agents is small in the
UK compared to the market worldwide. It is therefore unlikely
that the major pharmaceutical companies will fund these initia-
tives unless there is a suggestion that if the new treatments
prove better they will become widely used and available.
However, if we in the UK wish to move forward we cannot stall
any more, and now have the mandate to treat. As more trials are
reported and initiated we must have more money in the system
so that the UK can be a participant or leader – this will not
happen if we do not have regimens other than MIC and MVP
on our menu of treatment options.
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